164 related articles for article (PubMed ID: 35972629)
1. Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study.
Shen P; Qiao B; Jin N; Wang S
Invest New Drugs; 2022 Dec; 40(6):1282-1289. PubMed ID: 35972629
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
3. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients.
Tang AL; O'Neil T; McDermott S; Tripathi S; Tikhtman R; Mark JR; Patil Y; Tabangin M; Altaye M; Wise-Draper TM; Zender CA
JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):935-939. PubMed ID: 36006622
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM; Lentsch EJ; Hornig JD; Skoner J; Stalcup S; Spampinato MV; Garrett-Mayer E; O'Quinn EC; Timmers CD; Romeo MJ; Wrangle JM; Young MRI; Rubinstein MP; Day TA; Lo RS; Paulos CM; Neskey DM
Cell Rep Med; 2021 Oct; 2(10):100426. PubMed ID: 34755137
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study.
Wu WJ; Liu Q; An PG; Wang L; Zhang JY; Chen Y; Zhang T; Zhang J
Front Immunol; 2023; 14():1282629. PubMed ID: 38035079
[TBL] [Abstract][Full Text] [Related]
6. The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study.
Yin GQ; Li ZL; Li D
Cancer Manag Res; 2022; 14():2133-2141. PubMed ID: 35795828
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
Zhang Z; Wu B; Peng G; Xiao G; Huang J; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Hong X; Wei J; Qin Y; Wan C; Zhong Y; Zhou Y; Zhao X; Leng Y; Zhang T; Wu G; Yao M; Zhang X; Yang K
Clin Cancer Res; 2022 Aug; 28(15):3268-3276. PubMed ID: 35766967
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).
Huang Y; Sun J; Li J; Zhu D; Dong M; Dou S; Tang Y; Shi W; Sun Q; Zhao T; Zhou Z; Zhou X; Liu Y; Li J; Zhu G; Zhang D; Chen Y; Zhu Q; Ju W; Zhong L
Int J Surg; 2023 Aug; 109(8):2220-2227. PubMed ID: 37288582
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.
Chen F; Qiu L; Mu Y; Sun S; Yuan Y; Shang P; Ji B; Wang Q
Front Surg; 2022; 9():893372. PubMed ID: 35983558
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
Zhai H; Li W; Jiang K; Zhi Y; Yang Z
Cancer Manag Res; 2022; 14():515-524. PubMed ID: 35173485
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.
Leddon JL; Gulati S; Haque S; Allen C; Palackdharry S; Mathews M; Kurtzweil N; Riaz MK; Takiar V; Nagasaka M; Patil Y; Zender C; Tang A; Cervenka B; McGrath J; Korn WM; Hinrichs BH; Jandarov R; Harun N; Sukari A; Wise-Draper TM
Clin Cancer Res; 2022 Aug; 28(16):3464-3472. PubMed ID: 35653116
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study.
Wang X; Huang J; Huang H; Liu Y; Ji C; Liu J
Invest New Drugs; 2023 Aug; 41(4):579-586. PubMed ID: 37368088
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma.
Chow JCH; Cheuk W; Cho WCS; Wong CF; Au DWY; Tam AHP; Wong RCW; Chan JCH; Law SCC; Ngan RKC; Wong KH; Cheung KM
JAMA Netw Open; 2023 Jul; 6(7):e2323890. PubMed ID: 37459093
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
Xiao W; Yuan Y; Wang S; Liao Z; Cai P; Chen B; Zhang R; Wang F; Zeng Z; Gao Y
Front Immunol; 2021; 12():798451. PubMed ID: 35095878
[TBL] [Abstract][Full Text] [Related]
18. The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus.
Lin JW; Hsu CP; Yeh HL; Chuang CY; Lin CH
J Chin Med Assoc; 2018 Jan; 81(1):18-24. PubMed ID: 29066057
[TBL] [Abstract][Full Text] [Related]
19. Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.
Yamakawa N; Umeda M; Yoshii Y; Mitsudo K; Noguchi M; Kusukawa J; Katakura A; Nakayama H; Sasaki M; Noguchi T; Ueda M; Bukawa H; Yagihara K; Horie A; Miyazaki A; Chikazu D; Tomihara K; Mishima K; Otsuru M; Asoda S; Fujiwara S; Ohyama Y; Kurita H; Kawamata H; Fukuda M; Shintani Y; Kobayashi T; Kanno T; Oh-Iwa I; Kawano K; Yamashita Y; Kobayashi W; Ohiro Y; Uzawa K; Ota Y; Kirita T
Oral Dis; 2024 Mar; 30(2):247-258. PubMed ID: 36519515
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
